Achieve Life Sciences closed at $6.98 on Nov 4, up 3.71%, 18.2% below its 52-week closing high. Volume of 1.4M shares was 1.08× its 20-day average (close to normal).
Split-adjusted performance: -0.7% over one month, +45.4% over six months, +36.6% over one year.
Short interest was 17.8M shares at the Oct 15 settlement, up 1.9% from the prior report (28.1% of float, 13.8 days to cover).
No reported quarters with price history yet.
Percentile among 15 companies (100 = best)
Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ACHVAchieve Life Sciences | $6.98 | +3.71% | +45.4% | — | — | — | $719.7M | |
| MYGNMyriad Genetics | $6.02 | −0.33% | +46.5% | −10.5% | −22.7% | — | $575.8M | Compare |
| QDELQuidelOrtho | $14.35 | +1.85% | +30.9% | +2.8% | −14.7% | — | $984.1M | Compare |
| TKNOAlpha Teknova | $7.37 | +0.41% | +102.5% | +18.5% | −26.0% | — | $454.7M | Compare |
| NTLAIntellia Therapeutics | $12.31 | +3.79% | −11.1% | −46.2% | −1392.3% | — | $1.72B | Compare |
| CLDXCelldex Therapeutics | $29.93 | +0.74% | −13.0% | −97.0% | −334104.5% | — | $2.35B | Compare |
| NEOGNeogen | $12.46 | +2.98% | +35.7% | +6.5% | −5.3% | — | $2.72B | Compare |
| ICCCImmucell | $10.37 | +1.17% | +19.7% | +11.5% | 25.5% | 119.6 | $94.2M | Compare |
| IMDXInsight Molecular Diagnostics | $2.65 | −3.28% | −47.3% | −53.9% | −4711.3% | — | $86.7M | Compare |
No recent articles focused on Achieve Life Sciences.
Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
